THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
The FDA has expanded approval of Amgen’s PCSK9 inhibitor Repatha (evolocumab), permitting use in adults at increased risk of major adverse cardiovascular events due to uncontrolled LDL cholesterol, ...
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
The collaboration with Amgen reduces out-of-pocket costs for patients and expands access to an innovative cholesterol-lowering therapy GoodRx (Nasdaq: GDRX), the leading platform for medication ...
Amgen’s Repatha was heralded recently in the media, generating headlines like "New Drug Prevents Heart Attacks in High-Risk Patients." But the company's stock then fell. Who should we believe and why?
Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy Alone Repatha is Now the First and Only ...
Most Medicare Part D plans include coverage for Repatha, though specific coverage details can vary among plans. Out-of-pocket costs for Repatha under Medicare Part D typically average around $49 per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results